Examiner Cite

Initial* No

Patent Number

Kind

publisher, city and/or country where published.

Code¹

Issue Date

Remove

Figures Appear

Pages, Columns, Lines where

Relevant Passages or Relevant

	Application Number		09902651	
	Filing Date		2001-07-12	
NFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	First Named Inventor	Hiroyı	uki NAKANE	
	Art Unit		1656	
	Examiner Name	David	vid J. Steadman	
	Attorney Docket Numb	er	77670/593	

U.S.PATENTS

Name of Patentee or Applicant

of cited Document

							1 -		
	1								
If you wisl	h to ad	d additional U.S. Pater	t citatio	n information p	lease click the	Add button.		Add	
			U.S.P.	ATENT APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite N	lo Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applica of cited Document		Relev	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1								
If you wisl	h to ad	d additional U.S. Publis	shed Ap	plication citatio	n information p	olease click the Add	butto	n. Add	
				FOREIGN PA	TENT DOCUM	IENTS		Remove	
Examiner Initial*		Foreign Document Number ³	Country Code ²		Publication Date	Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	Ts
	1								
If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
NON-PATENT LITERATURE DOCUMENTS Remove									
Examiner	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item								

(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),

Initials* No

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09902651
Filing Date		2001-07-12
First Named Inventor	Hiroyuki NAKANE	
Art Unit		1656
Examiner Name	David	J. Steadman
Attorney Docket Number		77670/593

hi OHNUMA, et al.: "Archaebacterial Ether-linked Lipid Biosynthetic Gene", Journal of Biological Chemis	ry
9, No. 20, pp. 14792-14797, 1994.	. [
ori CKADA, et al. "Cioning of the sdsA Gene Encoding Solanesyl Diphosphate Syrithase from Phodobat atus and its Functional Expression in Escherichia coli and Saccharomyces cerevisiae", Journal of Bacte 97, Vol. 179, No. 19, pp. 5992-5998.	
in OHNUMA, et al. "A Role of the Amino Acid Residue Located on the Fifth Position before the First Asp et of Gramesy Diphosphate Synthase on Determination of the Final Product", The Journal of Biological stry, Vol. 271, No. 48, pp. 30748-30754.	rtate-
ional non-patent literature document citation information please click the Add button Add	
EXAMINER SIGNATURE	
Date Considered	
ional non-patent literature document citation information please click the Add button EXAMINER SIGNATURE	

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04, 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. Applicant is to place a check mark here if English language translation is attached

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09902651
Filing Date		2001-07-12
First Named Inventor	Hiroyuki NAKANE	
Art Unit		1656
Examiner Name	David	J. Steadman
Attorney Docket Numb	er	77670/593

CERTIFICATION STATEMENT

Please see 37	CFR '	1.97	and	1.98 to	make the	appropriate	selection(s)	ľ
---------------	-------	------	-----	---------	----------	-------------	------------	----	---

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(e)(1)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(e)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Shown W O'Dowd

X None

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

form of the signature.			
Signature	/Shawn W. O'Dowd/	Date (YYYY-MM-DD)	2012-01-09

Registration Number

34 687

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Comments o

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicide to is coluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan KORice is to process andior examine your submission related to a patient application or patient. If you do not furnish the requested privacy is the principal purpose of which the individual control of the privacy is a process and or examine your submission related to a patient application or patient. If you do not furnish the requested many privacy is the privacy of the privacy is provided by the privacy in the privacy is the privacy in the privacy is the privacy in the privacy is the privacy in the privacy in the privacy is the privacy in the privacy in the privacy in the privacy is the privacy in the privacy in the privacy in the privacy in the privacy is the privacy in the privacy in the privacy is the privacy in the privacy in the privacy in the privacy is the privacy in the privacy is the privacy in th

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subiect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S.C. 552(am).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, cuting an inspection of records conducted by GSA is part of that apency's responsibility to recommend improvements in records management practices and programs, under authority of 4 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations abavit individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
 the application presume to 58 U.S. C. 159 or issuance of a patient pursuant to 55 U.S. C. 151. Further, a record
 may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public fifthe record was filled in
 an application which became abandoned or in which the proceedings were terminated and which application is
 referenced by either a published application, one of public inspections or an issued patient.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.